

Primary Investigator

Jonathan Silverberg, MD, PhD, MPH

Dr. Silverberg specializes in dermatoepidemiology with a focus on comorbidities and quality of life. His research interests include the patient-and-population-based burden of atopic dermatitis and other chronic inflammatory skin diseases.

Study Sponsored By:

AbbVie, Inc.

abbvie

Interested?

Schedule your screening visit to find out if you are eligible to participate in AD Up by contacting our study team at:

1-312-503-5945

NUderm-research@northwestern.edu

Who We Are

About Us

Our clinical dermatopharmacology unit consists of an active clinical trials group for industry-sponsored studies as well as investigator-initiated outcomes research.

Contact Us

Northwestern University
Department of Dermatology
Clinical Trials Unit

676 N. St. Clair Street. Suite 1600
Chicago, IL 60611

Visit us online:
www.tinyurl.com/NUFeinbergCTU

Northwestern Medicine®
Feinberg School of Medicine



AD Up

A research study on atopic dermatitis / eczema

IRB # STU00207896

Participants Invited

About AD Up

AD Up is a clinical research study that will look at how safe and effective upadacitinib in combination with topical corticosteroids (TCS) is in helping to relieve the symptoms of moderate to severe atopic eczema (also known as atopic dermatitis).

Upadacitinib is a novel selective orally available Janus kinase-1 (JAK1) inhibitor with the potential to decrease skin inflammation and itch. Results from a Phase 2 study in AD showed that upadacitinib doses of 15 mg to 30 mg per day had efficacy and safety profile that can benefit patients with moderate to severe AD. Clinical studies have established that upadacitinib is effective in the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. The mechanism of action, combined with demonstration of clinical benefit in inflammatory diseases provides the rationale for evaluating upadacitinib in moderate to severe AD.

During this study, 1 out of every 3 participants will take a placebo. Placebo-controlled studies like this one (where some participants receive the investigational medication and some receive a placebo), help us make sure that any effects we see are due to taking upadacitinib and not to other factors.

Eligibility Criteria

- ✓ Between the ages of 12 and 75
- ✓ Have a diagnosis of atopic dermatitis (AD) for at least 3 years prior to participation

Participants are needed for a study evaluating the effectiveness and safety of upadacitinib in combination with topical corticosteroids (TCS) on individuals with moderate to severe atopic dermatitis

- ✓ Have documented history of inadequate response to treatment with topical medication or for whom topical treatment are medically inadvisable within 6 months prior to the baseline visit.
- ✓ AD involvement of ≥10% body surface area at screening and at randomization
- ✓ Agree to use a stable dose of emollient at least twice daily for at least 7 days before randomization
- ✓ Agree to discontinue use of excluded medications/treatment for at least 4 weeks before randomization
- ✓ Use effective birth control

Join a Clinical Study Investigating the Treatment of Eczema

Length of Participation

Participation in AD Up will be approximately 3 years. Participants will be required to visit the dermatology clinic at the downtown Chicago area for in-person assessments and study drug administration.

The study is split into four periods:

- A **screening period** of 35 days
- A **double-blind period** of 16 weeks
- A **blinded extension period** of up to 136 week
- A **follow-up period** of 30 days

Participants will be compensated.